Is Prostate Cancer Hereditary | Prostate Cancer Risk Factors

Prostate cancer is the most common cancer in men in the United Kingdom, with tens of thousands of new diagnoses each year. Is Prostate Cancer Hereditary? For individuals and clinicians, understanding the genetic component of prostate cancer is vital.

It moves conversations beyond general awareness and towards targeted screening, personalised risk management, and advanced treatment strategies. While age and ethnicity are well-known risk factors, a family history of the disease is arguably the most critical factor that signals an inherited, or hereditary, predisposition.

Is Prostate Cancer Hereditary?

The notion that prostate cancer is an entirely random event is scientifically outdated. Research, including findings from the UK Genetic Prostate Cancer Study (UKGPCS), confirms a substantial genetic link:

• Significant Genetic Component: Inherited factors are thought to account for 40% to 50% of the overall risk of developing prostate cancer.
• Hereditary vs. Sporadic: While most cases are considered ‘sporadic’ (occurring by chance), an estimated 5% to 12% of all prostate cancer diagnoses are classified as truly hereditary, meaning they are driven by a specific, high-risk gene mutation passed down through a family. This percentage is even higher—around 12% to 15%—for men with metastatic (advanced) prostate cancer.

Who is at Increased Risk?

A detailed family history is the first and most powerful tool for identifying an elevated, potentially hereditary, risk. In the UK, a man’s risk is significantly increased if he has:

Family History Criterion	Approximate Increased Risk	Key Implications
One first-degree relative (father, brother, or son) with prostate cancer.	Double (2x) the risk of the general population.	Should prompt a discussion about starting PSA screening earlier.
Two or more first-degree relatives with prostate cancer.	Up to 5 times the risk of the general population.	Indicates a high-risk family requiring specialist genetic assessment.
A relative diagnosed with prostate cancer under the age of 55.	Implies a higher likelihood of an aggressive, inherited mutation.	Warrants urgent specialist referral.
A family history of related cancers, particularly on the mother’s or father’s side.	Suggests a mutation in a gene linked to multiple cancers Eg., BRCA2).	This includes breast, ovarian, pancreatic, and male breast cancer.

Mutation of Prostate Cancer

The genetic predisposition to prostate cancer is often linked to mutations in tumour suppressor genes. These genes are crucial for repairing DNA damage. When they are faulty (mutated), it significantly increases cancer risk.

1. BRCA2 and BRCA1 Mutations

The BRCA2 gene (Breast Cancer gene 2) is the most significant high-risk gene identified in hereditary prostate cancer.

• Elevated Risk: Men who inherit a harmful BRCA2 mutation face a lifetime prostate cancer risk of approximately 19% to 60% (compared to around 10% in the general population by age 80).
• Aggressive Disease: Crucially, BRCA2-associated prostate cancers are often diagnosed at a younger age and are statistically more likely to be aggressive and rapidly progress to a metastatic stage.
• Clinical Impact: Identifying a BRCA2 mutation in a patient can directly influence treatment, as these men may benefit from targeted therapies like PARP inhibitors (Poly(ADP-ribose) polymerase inhibitors) as a standard-of-care treatment in metastatic disease.

The BRCA1 gene also confers an increased risk, though generally lower than BRCA2, estimated at 7% to 25% lifetime risk.

2. HOXB13

A mutation in the HOXB13 gene is strongly associated with an increased risk of developing prostate cancer, particularly early-onset disease. The estimated lifetime risk is substantial, ranging from 33% to 60%.

3. DNA Mismatch Repair (Lynch Syndrome)

Mutations in genes like MLH1, MSH2, MSH6, and PMS2 are known to cause Lynch syndrome (also known as Hereditary Non-Polyposis Colorectal Cancer or HNPCC). While primarily linked to bowel and endometrial cancer, it also moderately increases the risk of prostate cancer (12% to 52% lifetime risk).

4. ATM and CHEK2

Mutations in the ATM and CHEK2 genes, which also play a role in DNA repair, are increasingly recognised as moderate-risk factors for prostate cancer. Also understand, Can Women Get Prostate Cancer.

Who Should Consider Genetic Testing?

For men with a strong family history, or those diagnosed with aggressive or metastatic disease, germline genetic testing (a blood or saliva test) is a crucial step recommended by UK clinical guidelines.

• Any man with metastatic prostate cancer, regardless of age or family history.
• Men with a strong family history of prostate, breast, ovarian, or pancreatic cancers, particularly on the same side of the family.
• Men diagnosed with prostate cancer under the age of 55.

Value of a Positive Result

Identifying an inherited mutation has profound implications for both the individual and their family:

• Precision Treatment: It opens up new, targeted therapeutic options (like PARP inhibitors) that are more effective against genetically mutated tumours.
• Targeted Screening for Relatives: The genetic information allows adult male and female relatives (who have a 50% chance of inheriting the mutation) to access genetic counselling and tailored surveillance programmes for prostate, breast, ovarian, and other associated cancers.
• Active Surveillance Decisions: For men with low-risk cancer who might otherwise be placed on ‘active surveillance,’ the presence of a BRCA2 mutation is a strong indicator that immediate, definitive treatment (such as surgery or radiotherapy) should be considered, due to the higher potential for aggressive disease progression.

Conclusion

Is Prostate Cancer Hereditary? Here the evidence is clear: prostate cancer is hereditary in a significant minority of cases, and a family history is a powerful indicator of this genetic risk. For anyone concerned about a pattern of cancer in their family, it is essential to discuss this with the best General Practitioner in Essex.

Identifying the hereditary link is not simply about risk prediction; it is about accessing precision medicine—the targeted screening, bespoke treatment, and crucial genetic counselling that can lead to earlier diagnosis and improved outcomes for both the individual and their wider family.

FAQs